Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of GS-9620 versus placebo in virally suppressed chronic hepatitis B
NL-OMON41916Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vesatolimod in Chronic Hepatitis B (CHB) (6 cohorts), sponsored by Gilead Sciences. Primary endpoints: Change in serum HBsAg from baseline to Week 24 and Safety and tolerability. Started Sep 2015; status: active, not recruiting.
02
Drugs
vesatolimod
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NL-OMON41916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41916.